Nonagen Bioscience announces CE mark for Oncuria® bladder cancer diagnostic

LOS ANGELES, June 16, 2022 /PRNewswire/— Nonagen Bioscience, a cancer diagnostics company, today announced CE marking for its Oncuria® immunoassay for bladder cancer. Nonagen Bioscience now has CE marking for its Oncuria® bladder cancer immunoassay, setting the stage for European sales....

Click to view original post